Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2
Sponsor: Alkermes, Inc.
Summary
The purpose of this study is to measure decreases in daytime sleepiness, and disease symptoms in participants with Narcolepsy Type 2 (NT2) when taking ALKS 2680 tablets compared with placebo tablets.
Official title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2 (Brilliance NT2 Study 303)
Key Details
Gender
All
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
176
Start Date
2026-04-22
Completion Date
2027-06
Last Updated
2026-05-26
Healthy Volunteers
No
Conditions
Interventions
ALKS 2680 Dose 1
Participants will receive ALKS 2680 tablets, daily, orally, for 12 weeks
ALKS 2680 Dose 2
Participants will receive ALKS 2680 tablets, daily, orally, for 12 weeks
ALKS 2680 Dose 3
Participants will receive ALKS 2680 tablets, daily, orally, for 12 weeks
Placebo
Participants will receive placebo tablets, daily, orally for 12 weeks
Locations (8)
Alkermes Investigational Site
Brandon, Florida, United States
Alkermes Investigational Site
Macon, Georgia, United States
Alkermes Investigational Site
Lansing, Michigan, United States
Alkermes Investigational Site
Cincinnati, Ohio, United States
Alkermes Investigational Site
Wyomissing, Pennsylvania, United States
Alkermes Investigational Site
Columbia, South Carolina, United States
Alkermes Investigational Site
Austin, Texas, United States
Alkermes Investigational Site
Sugar Land, Texas, United States